Cogent Biosciences, Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Its current programs center on targeted small-molecule medicines designed to address specific molecular drivers of serious conditions, with a lead emphasis on KIT-mutated diseases such as systemic mastocytosis and certain gastrointestinal stromal tumors. The company is also advancing additional research programs across other genetically driven cancers and rare diseases, including areas involving FGFR, ErbB2, PI3Kα, KRAS, and JAK2 alterations. Cogent Biosciences works within the biopharmaceutical and precision oncology markets, where highly selective therapies are used to match treatment to disease biology. Headquartered in Waltham, Massachusetts, Cogent Biosciences concentrates on translating molecular insights into specialized treatment options for patients with unmet medical needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Andrew R. Robbins M.B.A.
- Employees
- 258
- Headquarters
- Waltham, MA, United States
- Website
- www.cogentbio.com